Adma Biologics, Inc. ADMA
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 18, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
10 paragraphs in Risk Factors of the 10-K filed Feb 25, 2026 with nothing like them in the 10-K filed Mar 18, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
Issues in the development and use of AI may result in reputational harm and increased liability exposure.
Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease.
Regulatory authorities may not accept data from foreign clinical studies or sites or may find that such data is not sufficiently representative of the population of the approving jurisdiction;
our customers’ inability to comply with the terms of our distribution agreements; and
On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM Credit Facilities”) consisting of (i) a term loan in the aggregate principal amount of $75 million, which was drawn in full on the JPM Closing Date, and (ii) a revolving credit facility in the aggregate principal amount of up to $225 million (collectively, the “JPM Loans”), none of which was drawn on the JPM Closing Date. The JPM Credit Facility has a maturity date of August 5, 2028.
Show the other 3
There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent.
Issues in the development and use of AI may result in reputational harm and increased liability exposure.
We have engaged a third-party firm to assist the Company with the development and deployment of an AI tool, ADMAlytics, to improve efficiencies across our supply chain, production, and commercial operations. This tool has been used to assist with activities including plasma pool composition and identifying other manufacturing efficiencies to streamline certain operational processes. While we have successfully implemented ADMAlytics in certain aspects of our commercial manufacturing and expanded its use throughout fiscal year 2025, the development, implementation, and ongoing use of AI technologies involve inherent risks. While ADMA has not experienced any issues to date, these risks include potential data inaccuracies, flawed assumptions, system errors, cybersecurity vulnerabilities, unintended outcomes, and difficulties in integrating AI-driven insights into complex and highly regulated manufacturing and operational environments. If ADMAlytics fails to perform as intended or produces unreliable or biased outputs, our reputation could be harmed and we could be subject to legal exposure, which could adversely affect our business, results of operations, and financial condition.
There may be and have been changes in legal and regulatory requirements that may materially impact our results of operation.
We may face new risks as a result of changes in legal and regulatory requirements that may impact our operations and future prospects. For example, the 2025 change in the U.S. federal administration, as well as changes in legal standards, including the reduced level of judicial deference due to administrative agencies following a 2024 Supreme Court decision, may and does introduce regulatory and legal uncertainties that impact our operations. New federal or state laws and regulations may be, and have been, passed or enforced differently than they were before, requiring that we adapt, which we may not be able to do, and expend additional resources to ensure that we are able to comply. New laws and regulations, or the enforcement of the same, may also adversely restrict how we conduct our business. There could also be changes in the FDA’s approval standards that could impact our ability to obtain and maintain product approvals and market our product candidates or that otherwise could impact the competitive market for our products. Legal and regulatory changes may additionally impact how we may market and sell our products and how they are reimbursed. We cannot predict the exact nature of any changes that may take place or whether and how they may impact our business and results of operation.
Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before
New in the latest 10-Q
9 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
10-Q
● our beliefs, plans and expectations regarding pending or threatened litigation and other legal proceedings;
Read in the 10-Q
Financial statements and notes
Nine Months Ended September 30, 2026 2025 (In thousands) ─────────────────────────────────────────────────────────────────────────────────────────────────────────── CASH FLOWS FROM OPERATING ACTIVITIES: Net income $133,034 $97,551 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 5,409 6,050 Gain on sale of plasma (7,980) - centers Loss on disposal of fixed 42 - assets Deferred income tax provision 2,569 9,848 Stock-based compensation 18,667 14,634 Amortization of debt discount 589 520 Loss - 3,336 on extinguishment of debt Amortization of license (107) (107) revenue Changes in operating assets and liabilities: Accounts receivable, net (10,794) (87,674) Inventories (59,650) (26,432) Prepaid expenses and other (2,514) (978) current assets Deposits and other assets 192 (261) Accounts payable 12,958 4,533 Accrued expenses 13,675 (5,427) Other current and non-current (934) (836) liabilities Net cash provided by 105,156 14,757 operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and (6,801) (21,491) equipment Acquisition of intangible (119) (124) assets Proceeds on the sales of 5,000 - assets held for sale Net cash used in investing (1,920) (21,615) activities CASH FLOWS FROM FINANCING ACTIVITIES: Ares term loan payments - (32,500) Ares revolving facility - (72,500) payments Ares revolving facility - 30,000 proceeds JPM term loan payments (1,875) (469) JPM revolving facility 125,000 75,000 proceeds Prepayment penalties on - (1,031) repayment of debt Taxes paid on vested (9,769) (9,383) restricted stock units Debt issuance costs - (2,224) Net proceeds from the 633 2,554 exercise of stock options Payment of end of term fee - (1,313) Acquisition of treasury stock (180,300) (23,038) Net cash used in financing (66,311) (34,904) activities Net increase (decrease) in cash and cash equivalents 36,925 (41,762) Cash and cash equivalents - beginning of period 87,630 103,147 Cash and cash equivalents - end of period $124,555 $61,385
Read in the 10-Q
Three stockholder derivative actions alleging substantially the same facts as the Securities Class Action have been filed to date: (1) Zunya v. Elms, et al., Case No. 2:26-cv-10811-ES-AME (D.N.J.) (the “Zunya Action”), filed on August 24, 2026; (2) Parris v. Elms, et al., Case No. 2:26-cv-11014-ES-AME (D.N.J.) (the “Parris Action”), filed on August 26, 2026; and (3) ES Trust v. Grossman, et al., Case No. 2:26-cv-11361-ES-AME (D.N.J.) (the “ES Trust Action,” and, collectively with the Zunya Action and Parris Action, the “Derivative Actions”), filed on September 2, 2026. The Derivative Actions were filed in the United States District Court for the District of New Jersey. The plaintiffs in the Derivative Actions purport to assert claims on the Company’s behalf against certain of the Company’s current and former executives and members of the Board for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, corporate waste, unjust enrichment, and violations of the Exchange Act. The Derivative Actions seek unspecified monetary and punitive damages, disgorgement of profits from the named defendants, an award of costs and expenses, including reasonable attorneys’ fees, and corporate governance reforms. On September 21, 2026, the Court consolidated the Derivative Actions with the new caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. The Company intends to move for a stay of the Derivative Actions pending resolution of the Securities Class Action.
Read in the 10-Q
The Company also received three demands to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law seeking documents related to the facts alleged in the Securities Class Action (the “Section 220 Demands”). The Company has responded to each of the Section 220 Demands and continues to discuss those responses with the requesting stockholders. The stockholders who served the Section 220 Demands may file additional Derivative Actions.
Read in the 10-Q
MD&A
Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025
Read in the 10-Q
Show the other 4
Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025
Read in the 10-Q
(b) Adjusted basic EPS is measured using basic weighted-average shares outstanding.
Read in the 10-Q
Legal proceedings
Three stockholder derivative actions alleging substantially the same facts as the Securities Class Action have been filed to date: (1) Zunya v. Elms, et al., Case No. 2:26-cv-10811-ES-AME (D.N.J.) (the “Zunya Action”), filed on August 24, 2026; (2) Parris v. Elms, et al., Case No. 2:26-cv-11014-ES-AME (D.N.J.) (the “Parris Action”), filed on August 26, 2026; and (3) ES Trust v. Grossman, et al., Case No. 2:26-cv-11361-ES-AME (D.N.J.) (the “ES Trust Action,” and, collectively with the Zunya Action and Parris Action, the “Derivative Actions”), filed on September 2, 2026. The Derivative Actions were filed in the United States District Court for the District of New Jersey. The plaintiffs in the Derivative Actions purport to assert claims on the Company’s behalf against certain of the Company’s current and former executives and members of our Board for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, corporate waste, unjust enrichment, and violations of the Securities Exchange Act of 1934, as amended. The Derivative Actions seek unspecified monetary and punitive damages, disgorgement of profits from the named defendants, an award of costs and expenses, including reasonable attorneys’ fees, and corporate governance reforms. On September 21, 2026, the Court consolidated the Derivative Actions with the new caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. We intend to move for a stay of the Derivative Actions pending resolution of the Securities Class Action.
Read in the 10-Q
We also received three demands to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law seeking documents related to the facts alleged in the Securities Class Action (the “Section 220 Demands”). We responded to each of the Section 220 Demands and continue to discuss those responses with the requesting stockholders. The stockholders who served the Section 220 Demands may file additional Derivative Actions.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 25, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Show the other 18
The first 23 of 39 are shown (at most 12 of each type).
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 25, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 18, 2025
Where each one is used
- jpm credit: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
- jpm loans: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
- jpmorgan taking: Our senior secured credit facility with JPMorgan Chase Bank, N.A. and certain other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in JPMorgan taking possession and disposing of any collateral.
- jpm closing: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
- reputational harm: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
- increased liability: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
- liability exposure: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
- lenders party: Our senior secured credit facility with JPMorgan Chase Bank, N.A. and certain other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in JPMorgan taking possession and disposing of any collateral.
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
1 paragraph of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.